Screener
Jazz Pharmaceuticals JAZZ Income Tax
Income Tax at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Interest expense, net | (39.9) | (53.7) |
| Foreign exchange gain (loss) | 2.5 | (0.2) |
| Income (loss) before income tax expense (benefit) and equity in loss of investees | 299.2 | (109.8) |
| Income tax expense (benefit) | 6.1 | (17.8) |
| Equity in loss of investees | — | 0.5 |
| Net income (loss) | $293.1 | $(92.5) |
| Net income (loss) per ordinary share: | ||
| Basic | $4.73 | $(1.52) |
Item 1.Financial Statements
FAQ
- What is Jazz Pharmaceuticals's income tax?
- Jazz Pharmaceuticals (JAZZ) reported income tax of $6.1M in Q1 2026.
- How has Jazz Pharmaceuticals's income tax changed year-over-year?
- Jazz Pharmaceuticals's income tax increased by 134.3% year-over-year, from -$17.8M to $6.1M.
- What is the long-term trend for Jazz Pharmaceuticals's income tax?
- Over 4 years (2021 to 2025), Jazz Pharmaceuticals's income tax has grown at a 5.0% compound annual growth rate (CAGR), from $228.58M to -$277.39M.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.
Ask your AI about Jazz Pharmaceuticals's income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude